William Blair Predicts Repligen’s Q2 Earnings (NASDAQ:RGEN)

Repligen Co. (NASDAQ:RGEN) – Stock analysts at William Blair reduced their Q2 2025 earnings per share (EPS) estimates for shares of Repligen in a research report issued on Wednesday, April 30th. William Blair analyst M. Larew now forecasts that the biotechnology company will post earnings of $0.41 per share for the quarter, down from their previous forecast of $0.45. The consensus estimate for Repligen’s current full-year earnings is $1.72 per share. William Blair also issued estimates for Repligen’s Q3 2025 earnings at $0.40 EPS, Q4 2025 earnings at $0.46 EPS, Q1 2026 earnings at $0.49 EPS and Q2 2026 earnings at $0.57 EPS.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, beating the consensus estimate of $0.35 by $0.04. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The firm had revenue of $169.17 million during the quarter, compared to analyst estimates of $163.65 million. During the same quarter in the previous year, the business earned $0.28 EPS. Repligen’s revenue for the quarter was up 10.4% compared to the same quarter last year.

Several other research firms have also commented on RGEN. StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a research note on Monday. Evercore ISI began coverage on Repligen in a research note on Tuesday, March 18th. They set an “in-line” rating and a $155.00 price objective for the company. Royal Bank of Canada dropped their price target on Repligen from $202.00 to $189.00 and set an “outperform” rating for the company in a research report on Wednesday. Wolfe Research upgraded Repligen from a “peer perform” rating to an “outperform” rating and set a $160.00 price target for the company in a research report on Tuesday. Finally, HC Wainwright restated a “buy” rating and issued a $180.00 price target on shares of Repligen in a research report on Friday, February 21st. Six equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Repligen presently has an average rating of “Moderate Buy” and a consensus target price of $173.25.

Repligen Price Performance

NASDAQ:RGEN opened at $137.20 on Thursday. Repligen has a 12 month low of $102.97 and a 12 month high of $182.52. The stock has a 50 day moving average of $138.22 and a two-hundred day moving average of $145.83. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The firm has a market cap of $7.70 billion, a P/E ratio of -269.02, a price-to-earnings-growth ratio of 4.54 and a beta of 1.27.

Insider Activity at Repligen

In other Repligen news, Director Margaret Pax acquired 250 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The shares were purchased at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the acquisition, the director now owns 1,043 shares of the company’s stock, valued at approximately $157,169.67. The trade was a 31.53 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. 1.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Signaturefd LLC grew its stake in shares of Repligen by 172.2% in the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 124 shares in the last quarter. Sava Infond d.o.o. purchased a new position in Repligen during the 4th quarter valued at about $29,000. Raiffeisen Bank International AG acquired a new position in Repligen in the 4th quarter valued at about $29,000. Itau Unibanco Holding S.A. purchased a new stake in Repligen during the fourth quarter worth about $40,000. Finally, UMB Bank n.a. lifted its position in shares of Repligen by 49.1% during the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 110 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.